18F-FDG PET and bone scintigraphy to search for bone metastasis of lung cancer;TEP au FDG-(18F) et scintigraphie du squelette dans a recherche de métastases osseuses du cancer broncho-pulmonaire

Revue de Pneumologie Clinique

Volumn 62, Issue 3, 2006, Pages 164-169

  Aflalo Hazan, V ^a   Gutman, F ^a   Raileanu, I ^a   Fretault J ^b   Kerrou, K ^a   Grahek, D ^a   Montravers, F ^a   Talbot, J N ^a  

^a HÔPITAL TENON   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Bone metastasis; Lung cancer; Positon emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BONE MALFORMATION; BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMAGING; LABORATORY; LUNG CANCER; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; TIME SERIES ANALYSIS;

EID: 33745878857     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8417(06)75432-3     Document Type: Article

References (20)

1. Dominioni L, Imperatori A, Rovera F, Ochetti A, Torrigiotti G, Paolucci M. Stage I non small cell lung carcinoma: analysis of survival and implications for screening. Cancer 2000;89:2334-44.
2. Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest 1990;97:1052-8.
3. Napoli LD, Hansen HH, Muggia FM, Twigg HL. The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes. Radiology 1973;108:17-21.
4. Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-20.
5. Halter G, Buck AK, Schirrmeister H, Aksoy E, Liewald F, Glatting G, et al. Lymph node staging in lung cancer using [18F]FDG-PET. Thorac Cardiovasc Surg 2004;52:96-101.
6. Konishi J, Yamazaki K, Tsukamoto E, Tamaki N, Onodera Y, Otake T, et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003;70:500-6.
7. Verboom P, Van Tinteren H, Hoekstra OS, Smit EF, Van Den Bergh JH, Schreurs AJ, et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003;30:1444-9.
8. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT. Radiology 1999;213:530-6.
9. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000]. Pneumologie 2001;55:367-77.
10. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003;139:879-92.
11. Gould MK, MacLean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-24.
12. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7.
13. Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Squire OD, Braban LE, et al. Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys 2002;29:366-71.
14. Fukuchi K, Yamaguchi M, Hayashida K, Ishida Y. Discrepancy between Tc-99m HMDP bone scan and F-18 FDG positron emission tomographic images in a patient with small cell lung cancer. Clin Nucl Med 2003;28:232-3.
15. Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 2003;5:26-31.
16. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-7.
17. Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317-25.
18. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-9.
19. Aquino SL, Fischman AJ. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer? Chest 2004;126:755-60.
20. Gontier E, Vaylet F, Bonardel G, Mantzarides M, Salles Y, Guigay J, et al. Tomographie à émission de positons au [18F]-FDG et métastases distates dans les cancers bronchopulmonaires. Rev Pneumol Clin 2005;61:248-57.